Picture of Arecor Therapeutics logo

AREC Arecor Therapeutics News Story

0.000.00%
gb flag iconLast trade - 00:00
HealthcareSpeculativeMicro CapSucker Stock

REG - Arecor Therapeutics - Progress of Phase I clinical study of AT278

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20231002:nRSB2656Oa&default-theme=true

RNS Number : 2656O  Arecor Therapeutics PLC  02 October 2023

Arecor Therapeutics plc

("Arecor" or the "Group")

 

Arecor provides update on progress of second Phase I clinical study of
ultra-rapid, ultra-concentrated insulin candidate AT278

 

Cambridge, UK, 2 October 2023: Arecor Therapeutics plc (AIM: AREC), the
biopharmaceutical group advancing today's therapies to enable healthier lives,
today announces that, in line with the update provided within its Interim
Results on 14 September, the Group has taken the decision to increase the
number of subjects within its ongoing Phase I clinical trial of ultra-rapid,
ultra-concentrated insulin candidate AT278.

 

The increase in the number of subjects within the study, from 32 to 42, will
increase the power of the study and, in turn, increase the value of the
results for patients with high insulin needs. Results are expected in early
2024.

 

Sarah Howell, Chief Executive Officer at Arecor, said: "Having already
demonstrated AT278's very promising profile in Type 1 diabetic patients, this
is a key clinical study for AT278 in the Type 2 patient population. The number
of people living with Type 2 diabetes is increasing, year-on-year, driven by
the obesity epidemic, and many patients are becoming insulin resistant,
requiring large volumes of insulin and multiple injections to manage their
condition, which is a heavy daily burden. AT278 has the potential to be the
first, and potentially only, highly concentrated and very rapid acting insulin
and thereby become the gold standard insulin for those with high daily insulin
needs. AT278 also has the potential to be a critical enabler in the
development of next generation miniaturised and longer wear insulin delivery
systems. And with all three major insulin device companies having access to
patch pump technology, we expect an acceleration in the development of these
next generation systems, which require a concentrated rapid acting insulin."

 

The trial is a double blind, randomised, crossover study comparing the
pharmacokinetic (PK) and pharmacodynamic (PD) profile following a single
subcutaneous dose of 0.5 U/Kg of AT278 (500 U/mL) with NovoRapid® (100 U/mL)
in 42 people with Type 2 diabetes in a euglycemic clamp setting. In addition,
the PK/PD profile following a single subcutaneous dose of 0.5 U/Kg Humulin-R
U500® will be evaluated in each of the participants.

 

-ENDS-

 

 

For more information, please contact:

 Arecor Therapeutics plc                         www.arecor.com (http://www.arecor.com/)
 Dr Sarah Howell, Chief Executive Officer        Tel: +44 (0) 1223 426060

                                                 Email: info@arecor.com (mailto:info@arecor.com)

 Susan Lowther, Chief Financial Officer          Tel: +44 (0) 1223 426060

                                                 Email: info@arecor.com (mailto:info@arecor.com)

 Mo Noonan, Communications                       Tel: +44 (0) 7876 444977

                                                 Email: mo.noonan@arecor.com (mailto:mo.noonan@arecor.com)

 Panmure Gordon (UK) Limited (NOMAD and Broker)
 Freddy Crossley, Emma Earl (Corporate Finance)  Tel: +44 (0) 20 7886 2500

 Rupert Dearden (Corporate Broking)

 ICR Consilium
 Chris Gardner, David Daley, Lindsey Neville     Tel: +44 (0) 20 3709 5700

                                                 Email: arecor@consilium-comms.com (mailto:arecor@consilium-comms.com)

 

Notes to Editors

 

About Arecor

Arecor Therapeutics plc is a globally focused biopharmaceutical group
transforming patient care by bringing innovative medicines to market through
the enhancement of existing therapeutic products. By applying our innovative
proprietary formulation technology platform, Arestat™, we are developing an
internal portfolio of proprietary products in diabetes and other indications,
as well as working with leading pharmaceutical and biotechnology companies to
deliver enhanced formulations of their therapeutic products. The Arestat™
platform is supported by an extensive patent portfolio. For further details
please see our website, www.arecor.com (http://www.arecor.com)

 

-

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCFSSFUFEDSESS

Recent news on Arecor Therapeutics

See all news